European Commission grants 3 NNZ-2591 Orphan designations

Melbourne, Australia:Neuren Pharmaceuticals (ASX: NEU) received notice that the European Commission has adopted the European Medicines Agency (EMA) recommendations to grant Orphan designation for NNZ-2591 in Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. Orphan designation in the EU enables sponsors to benefit from incentives including free protocol assistance, fee reductio